• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Why is the Creso Share Price Falling? (ASX:CPH)

Like 0

By Kiryll Prakapenka, Wednesday, 17 November 2021

The Creso Pharma [ASX:CPH] share price is falling as ASIC probes EverBlu Capital, whose executive chairman also serves as CPH’s non-executive chair and co-founder.

The Creso Pharma Ltd [ASX:CPH] share price is falling as ASIC probes EverBlu Capital, whose executive chairman also serves as CPH’s non-executive chair and co-founder.

CPH share price is currently trading at 11 cents per share, down 8.20%.

ASX CPH - Creso Share Price ChartSource: Tradingview.com

CPH management caught up in ASIC probe

CPH shares are under selling pressure today, following reports on raids of EverBlu Capital, a Sydney broker.

Adam Blumenthal — Creso’s co-founder and non-executive chairman — also serves as an executive chair at EverBlu.

As the Australian Financial Review noted, the exact nature of the investigation and purpose behind the raids are not yet publicly known.

Creso and EverBlu don’t only have Mr Blumenthal as a connection.

EverBlu was recently named CPH’s corporate adviser in a Creso options issue prospectus last month.

Today’s dip in the CPH share price may suggest some investors are worried the ASIC investigation could ensnare Creso management.

EverBlu’s spokesperson declined to comment on whether ASIC’s investigation related to Creso.

How to Limit Your Risks While Trading Volatile Stocks. Learn more.

Creso releases response

Fielding questions from the ASX regarding the developments — which spurred elevated trading activity in CPH stock — Creso said it was not aware of any information that could explain today’s sell-off.

Regarding Mr Bluementhal’s involvement with EverBlu, Creso offered the following response (emphasis added):

‘The Company is aware of two articles published by the Australian Financial Review today, which reported that the Australian Federal Police were executing a search warrant at the Sydney offices of Everblu Capital, of which Creso Pharma Limited’s Chairman, Adam Blumenthal, is a director.

‘The Company is yet to be able to independently verify the nature of the enquiry or determine whether the matter relates to Creso Pharma Limited.

‘The Company confirms, however, that it has not been served with any notices from any regulatory body in connection with the matter. As a result, the Company does not consider there to be any basis for it to make public announcement in relation to this matter. Otherwise, the Company is not aware of any other explanation for the recent trading in its securities.’

Clearly, the market will have to wait for more details to emerge from ASIC’s investigations to determine the extent — if any — of Creso’s involvement with the recent raids on EverBlu.

The small-cap sector is fraught with risk…and opportunity.

But it’s all about knowing how to find the right sorts of companies before they explode.

If you’re interested in exploring small-cap stocks, then I recommend reading this recent report from our small-caps expert, Ryan Clarkson-Ledward.

Get the free report here.

Regards,

Kiryll Prakapenka,

For Money Morning

PS: Our publication Money Morning is a fantastic place to start on your investment journey. We talk about the big trends driving the most innovative stocks on the ASX. Learn all about it here

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The Canary is Coughing
    By Charlie Ormond

    US employment data has long served as an early warning system for the global economy. When American workers start losing jobs, trouble tends to follow…For markets, for Australia, and eventually for your portfolio.

  • The Backdoor Entry: Why Majors Buy 10% Stakes Years Before 100% Takeovers
    By James Cooper

    When mining majors take strategic stakes in juniors, it signals serious interest. Learn why these small bites precede billion-dollar takeover deals.

  • Copper’s Christmas Breakout and a New Stock Idea
    By Murray Dawes

    Hopes for a Santa rally are building as the S&P 500 and Nasdaq just confirmed a weekly buy pivot, with odds of a US rate cut now close to 100%. In today’s Closing Bell, we look at how powerful these weekly trends can be.

Primary Sidebar

Latest Articles

  • The Canary is Coughing
  • The Backdoor Entry: Why Majors Buy 10% Stakes Years Before 100% Takeovers
  • Copper’s Christmas Breakout and a New Stock Idea
  • The Problem with Exponentials
  • Get ready! Mainstream investors are going for gold

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988